Compare Sana Biotechnology Inc (SANA) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Health Care Select Sector SPDR Fund — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Health Care Select Sector SPDR Fund trades at $170.66 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 52× Sana Biotechnology Inc's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| SANA | XLV | |
|---|---|---|
Market Cap | $836.71M | $43.48B |
Volume | 4,507,444 | 11,121,431 |
Sector | Health | — |
52-Week High | $5.92 | $175.68 |
52-Week Low | $2.68 | $141.95 |
Typical Hold Time | 23 Days | 100 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
XLV trades at $170.86, up 1.21% with a bearish technical signal from moving averages while oscillators remain neutral. The healthcare ETF shows strong cost advantages with a 0.08% expense ratio compared to peers, holding 61 diversified healthcare stocks from the S&P 500. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and political volatility.
The ETF offers defensive exposure to healthcare with low costs, though technical indicators suggest near-term pressure. Key risks include sector-specific regulatory changes and election uncertainty, while the fund's diversification provides stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
